Literature DB >> 23729215

Novel neutralising antibodies targeting the N-terminal helical region of the transmembrane envelope protein p15E of the porcine endogenous retrovirus (PERV).

Alexander Waechter1, Joachim Denner.   

Abstract

Previously, immunising different species with the transmembrane envelope protein p15E of the porcine endogenous retrovirus (PERV), neutralising antibodies were induced which recognised epitopes in the fusion peptide proximal region (FPPR) and in the membrane-proximal external region (MPER). Only the MPER-specific antibodies were shown to neutralise and these antibodies targeted epitopes in the MPER similarly localised as the epitopes recognised by antibodies broadly neutralising HIV-1 such as 2F5 and 4E10. To study whether neutralising antibodies could be induced immunising with subunits of p15E, recombinant proteins corresponding to the N-terminal, the C-terminal helical region (NHR, CHR) and a p15E with a mutation in the Cys-Cys loop were produced. Whereas none of these antigens induced MPER-specific neutralising antibodies, the animals immunised with the FPPR/NHR subunit and the mutated p15E produced neutralising antibodies binding to the NHR. Therefore, for the first time, antibodies specific for the NHR and neutralising PERV were described.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23729215     DOI: 10.1007/s12026-013-8430-y

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  45 in total

1.  Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.

Authors:  D M Eckert; P S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

Review 2.  Membrane-transferring regions of gp41 as targets for HIV-1 fusion inhibition and viral neutralization.

Authors:  Nerea Huarte; Maier Lorizate; Enrique Pérez-Payá; José L Nieva
Journal:  Curr Top Med Chem       Date:  2011-12       Impact factor: 3.295

3.  A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope.

Authors:  Michael D Miller; Romas Geleziunas; Elisabetta Bianchi; Simon Lennard; Renee Hrin; Hangchun Zhang; Meiqing Lu; Zhiqiang An; Paolo Ingallinella; Marco Finotto; Marco Mattu; Adam C Finnefrock; David Bramhill; James Cook; Debra M Eckert; Richard Hampton; Mayuri Patel; Stephen Jarantow; Joseph Joyce; Gennaro Ciliberto; Riccardo Cortese; Ping Lu; William Strohl; William Schleif; Michael McElhaugh; Steven Lane; Christopher Lloyd; David Lowe; Jane Osbourn; Tristan Vaughan; Emilio Emini; Gaetano Barbato; Peter S Kim; Daria J Hazuda; John W Shiver; Antonello Pessi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-03       Impact factor: 11.205

4.  Structural analysis and assembly of the HIV-1 Gp41 amino-terminal fusion peptide and the pretransmembrane amphipathic-at-interface sequence.

Authors:  Maier Lorizate; Igor de la Arada; Nerea Huarte; Silvia Sánchez-Martínez; Beatriz G de la Torre; David Andreu; José L R Arrondo; José L Nieva
Journal:  Biochemistry       Date:  2006-12-05       Impact factor: 3.162

5.  Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41.

Authors:  Donna L Montgomery; Ying-Jie Wang; Renee Hrin; Micah Luftig; Bin Su; Michael D Miller; Fubao Wang; Peter Haytko; Lingyi Huang; Salvatore Vitelli; Jon Condra; Xiaomei Liu; Richard Hampton; Andrea Carfi; Antonello Pessi; Elisabetta Bianchi; Joseph Joyce; Chris Lloyd; Romas Geleziunas; David Bramhill; Vicki M King; Adam C Finnefrock; William Strohl; Zhiqiang An
Journal:  MAbs       Date:  2009-09-08       Impact factor: 5.857

6.  Neutralization of porcine endogenous retrovirus by antibodies against the membrane-proximal external region of the transmembrane envelope protein.

Authors:  Alexander Waechter; Magdalena Eschricht; Joachim Denner
Journal:  J Gen Virol       Date:  2012-12-05       Impact factor: 3.891

7.  Functional links between the fusion peptide-proximal polar segment and membrane-proximal region of human immunodeficiency virus gp41 in distinct phases of membrane fusion.

Authors:  Anna K Bellamy-McIntyre; Chan-Sien Lay; Séverine Baär; Anne L Maerz; Gert H Talbo; Heidi E Drummer; Pantelis Poumbourios
Journal:  J Biol Chem       Date:  2007-05-25       Impact factor: 5.157

8.  Structural basis of HIV-1 neutralization by affinity matured Fabs directed against the internal trimeric coiled-coil of gp41.

Authors:  Elena Gustchina; Mi Li; John M Louis; D Eric Anderson; John Lloyd; Christian Frisch; Carole A Bewley; Alla Gustchina; Alexander Wlodawer; G Marius Clore
Journal:  PLoS Pathog       Date:  2010-11-11       Impact factor: 6.823

9.  Crystal structure and size-dependent neutralization properties of HK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41.

Authors:  Charles Sabin; Davide Corti; Victor Buzon; Mike S Seaman; David Lutje Hulsik; Andreas Hinz; Fabrizia Vanzetta; Gloria Agatic; Chiara Silacci; Lara Mainetti; Gabriella Scarlatti; Federica Sallusto; Robin Weiss; Antonio Lanzavecchia; Winfried Weissenhorn
Journal:  PLoS Pathog       Date:  2010-11-18       Impact factor: 6.823

10.  HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodies.

Authors:  Ji Wang; Pei Tong; Lu Lu; Leilei Zhou; Liling Xu; Shibo Jiang; Ying-hua Chen
Journal:  PLoS One       Date:  2011-03-31       Impact factor: 3.240

View more
  12 in total

1.  Screening pigs for xenotransplantation: expression of porcine endogenous retroviruses in transgenic pig skin.

Authors:  Magdalena Kimsa-Dudek; Barbara Strzalka-Mrozik; Malgorzata W Kimsa; Irena Blecharz; Joanna Gola; Bartlomiej Skowronek; Adrian Janiszewski; Daniel Lipinski; Joanna Zeyland; Marlena Szalata; Ryszard Slomski; Urszula Mazurek
Journal:  Transgenic Res       Date:  2015-03-27       Impact factor: 2.788

2.  Sequence variation of koala retrovirus transmembrane protein p15E among koalas from different geographic regions.

Authors:  Yasuko Ishida; Chelsea McCallister; Nikolas Nikolaidis; Kyriakos Tsangaras; Kristofer M Helgen; Alex D Greenwood; Alfred L Roca
Journal:  Virology       Date:  2014-11-22       Impact factor: 3.616

Review 3.  Islet cell xenotransplantation: a serious look toward the clinic.

Authors:  Kannan P Samy; Benjamin M Martin; Nicole A Turgeon; Allan D Kirk
Journal:  Xenotransplantation       Date:  2014-05-08       Impact factor: 3.907

Review 4.  Cardiac xenotransplantation: a promising way to treat advanced heart failure.

Authors:  Songren Shu; Jie Ren; Jiangping Song
Journal:  Heart Fail Rev       Date:  2022-01       Impact factor: 4.214

5.  Cytotoxic Effects during Knock Out of Multiple Porcine Endogenous Retrovirus (PERV) Sequences in the Pig Genome by Zinc Finger Nucleases (ZFN).

Authors:  Marwan Semaan; Daniel Ivanusic; Joachim Denner
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

Review 6.  Review on porcine endogenous retrovirus detection assays--impact on quality and safety of xenotransplants.

Authors:  Antonia W Godehardt; Michael Rodrigues Costa; Ralf R Tönjes
Journal:  Xenotransplantation       Date:  2015-01-31       Impact factor: 3.907

Review 7.  Can Antiretroviral Drugs Be Used to Treat Porcine Endogenous Retrovirus (PERV) Infection after Xenotransplantation?

Authors:  Joachim Denner
Journal:  Viruses       Date:  2017-08-08       Impact factor: 5.048

Review 8.  Preventing transfer of infectious agents.

Authors:  Joachim Denner; Nicolas J Mueller
Journal:  Int J Surg       Date:  2015-08-24       Impact factor: 6.071

Review 9.  Why was PERV not transmitted during preclinical and clinical xenotransplantation trials and after inoculation of animals?

Authors:  Joachim Denner
Journal:  Retrovirology       Date:  2018-04-02       Impact factor: 4.602

10.  A Comprehensive Strategy for Screening for Xenotransplantation-Relevant Viruses in a Second Isolated Population of Göttingen Minipigs.

Authors:  Luise Krüger; Yannick Kristiansen; Emelie Reuber; Lars Möller; Michael Laue; Christian Reimer; Joachim Denner
Journal:  Viruses       Date:  2019-12-29       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.